Search results
EHA 2024: Novartis Scemblix takes on all TKIs in head-to-head CML trial
Clinical Trials Arena via Yahoo Finance· 1 day agoWhile the differences in side effect rates...associated side effects less suitable. Given the...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 10 hours agoCLL and ...mutation, there is still a need for treatments that provide durable responses and extend...
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia
Digital Journal· 13 hours agoVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments ...
MD Anderson Research Highlights: EHA 2024 Special | Newswise
Newswise· 5 days agoThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research, and prevention. Thes
Syndax reports encouraging results from AML treatment trials By Investing.com
Investing.com· 3 days agoSyndax Pharmaceuticals (NASDAQ: NASDAQ:SNDX), a clinical stage biopharmaceutical company, has...
Age is just a number: Immune cell ‘epigenetic cl | Newswise
Newswise· 6 days agoNewswise — (MEMPHIS, Tenn. – June 12, 2024) While most cell types experience a functional decline...
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
KPVI· 4 days ago- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those receiving prior venetoclax
Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of...
Benzinga· 2 days agoElectra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of clinical ...
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
Zacks via Yahoo Finance· 3 days agoShattuck (STTK) will now focus on higher-risk myelodysplastic syndromes and TP53 mutant acute...
Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with...
KSAN - KLST San Angelo· 7 days agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the ...